Karo Bio reports positive results from diabetes study
Karo Bio, a drug discovery and development company, has reported that compound KB3305, a liver selective antagonist for the glucocorticoid receptor, showed clinically relevant and statistically significant effects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.